[ad_1]
Gov. Ron DeSantis signed a settlement agreement authorizing the issuance of a new medical marijuana license to eight different nurseries.
This arrangement was announced for the first time Tuesday by the newspaper POLITICO Florida Arek Sarkissian.
The eight nurseries will receive a marijuana license for medical purposes Florida Department of Health Bill's nursery, DeLeon bromeliads, Dewar nurseries, Hart nursery, Perkins nursery, Redland nursery, Spring Oaks greenhouse and Tree King farm.
These companies will add to the 14 operators already active in Florida.
Under the 2014 law creating the state's medical marijuana program, all these nurseries had applied for licenses and were eventually prosecuted after being refused. Only five licenses were available at the time.
As noted by POLITICO Florida, six of the nurseries had joined a lawsuit that had resulted in A 2018 decision of Administrative Law Judge John Van Laningham paving the way for the issuance of a new license at Nature's Way Nursery in Miami. It was the latest new license issued by the Ministry of Health.
Van Laningham described the existing application process as a "garbage dump light" in this decision.
A separate trialFlorigrown of Tampa challenged the constitutionality of a 2017 law limiting available licenses and requiring a vertical integration licensing system.
In this system, marijuana suppliers are allowed to play the role of jack-of-all traders by growing, processing and selling marijuana for medical purposes. Some companies are demanding licenses to participate in part of the process in order to free control of the industry by a limited number of organizations.
The eight new licenses to be issued under the new settlement agreement are vertical integration licenses. Now three of these licenses remain with the Ministry of Health.
DeSantis' decision to expand marijuana growers for medical purposes is in line with the industry's previous actions with respect to the industry. In March, DeSantis signed an invoice allowing a smokable form of the plant to be sold.
The projections generated the industry more than $ 2 billion in annual revenue within five years. More than 200,000 patients are currently allowed to buy the drug.
[ad_2]
Source link